Literature DB >> 10694730

What do we mean by validating a prognostic model?

D G Altman1, P Royston.   

Abstract

Prognostic models are used in medicine for investigating patient outcome in relation to patient and disease characteristics. Such models do not always work well in practice, so it is widely recommended that they need to be validated. The idea of validating a prognostic model is generally taken to mean establishing that it works satisfactorily for patients other than those from whose data it was derived. In this paper we examine what is meant by validation and review why it is necessary. We consider how to validate a model and suggest that it is desirable to consider two rather different aspects - statistical and clinical validity - and examine some general approaches to validation. We illustrate the issues using several case studies. Copyright 2000 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2000        PMID: 10694730     DOI: 10.1002/(sici)1097-0258(20000229)19:4<453::aid-sim350>3.0.co;2-5

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  374 in total

1.  Derivation versus validation.

Authors:  A Wade
Journal:  Arch Dis Child       Date:  2000-12       Impact factor: 3.791

2.  STrengthening the reporting of OBservational studies in Epidemiology-Molecular Epidemiology (STROBE-ME): an extension of the STROBE statement.

Authors:  Valentina Gallo; Matthias Egger; Valerie McCormack; Peter B Farmer; John P A Ioannidis; Micheline Kirsch-Volders; Giuseppe Matullo; David H Phillips; Bernadette Schoket; Ulf Stromberg; Roel Vermeulen; Christopher Wild; Miquel Porta; Paolo Vineis
Journal:  Eur J Epidemiol       Date:  2011-10-29       Impact factor: 8.082

3.  Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration.

Authors:  Douglas G Altman; Lisa M McShane; Willi Sauerbrei; Sheila E Taube
Journal:  BMC Med       Date:  2012-05-29       Impact factor: 8.775

4.  Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration.

Authors:  Douglas G Altman; Lisa M McShane; Willi Sauerbrei; Sheila E Taube
Journal:  PLoS Med       Date:  2012-05-29       Impact factor: 11.069

5.  External validity of risk models: Use of benchmark values to disentangle a case-mix effect from incorrect coefficients.

Authors:  Yvonne Vergouwe; Karel G M Moons; Ewout W Steyerberg
Journal:  Am J Epidemiol       Date:  2010-08-31       Impact factor: 4.897

6.  In primary care, when is chest pain due to coronary artery disease?

Authors:  Richard J Stevens; Daniel Lasserson
Journal:  CMAJ       Date:  2010-07-05       Impact factor: 8.262

Review 7.  Predictive and prognostic models in radical prostatectomy candidates: a critical analysis of the literature.

Authors:  Giovanni Lughezzani; Alberto Briganti; Pierre I Karakiewicz; Michael W Kattan; Francesco Montorsi; Shahrokh F Shariat; Andrew J Vickers
Journal:  Eur Urol       Date:  2010-08-06       Impact factor: 20.096

8.  External validity of two nomograms for predicting distant brain failure after radiosurgery for brain metastases in a bi-institutional independent patient cohort.

Authors:  Roshan S Prabhu; Robert H Press; Danielle M Boselli; Katherine R Miller; Scott P Lankford; Robert J McCammon; Benjamin J Moeller; John H Heinzerling; Carolina E Fasola; Kirtesh R Patel; Anthony L Asher; Ashley L Sumrall; Walter J Curran; Hui-Kuo G Shu; Stuart H Burri
Journal:  J Neurooncol       Date:  2017-12-07       Impact factor: 4.130

9.  Coronary risk assessment among intermediate risk patients using a clinical and biomarker based algorithm developed and validated in two population cohorts.

Authors:  D S Cross; C A McCarty; E Hytopoulos; M Beggs; N Nolan; D S Harrington; T Hastie; R Tibshirani; R P Tracy; B M Psaty; R McClelland; P S Tsao; T Quertermous
Journal:  Curr Med Res Opin       Date:  2012-11       Impact factor: 2.580

10.  Limited-sampling strategies for anidulafungin in critically ill patients.

Authors:  Marjolijn J P van Wanrooy; Johannes H Proost; Michael G G Rodgers; Jan G Zijlstra; Donald R A Uges; Jos G W Kosterink; Tjip S van der Werf; Jan-Willem C Alffenaar
Journal:  Antimicrob Agents Chemother       Date:  2014-12-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.